See more : CB Industrial Product Holding Berhad (CIHPF) Income Statement Analysis – Financial Results
Complete financial analysis of Athira Pharma, Inc. (ATHA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Athira Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Melco International Development Limited (0200.HK) Income Statement Analysis – Financial Results
- Jy Gas Limited (1407.HK) Income Statement Analysis – Financial Results
- Tokyo Individualized Educational Institute, Inc. (4745.T) Income Statement Analysis – Financial Results
- PT Sreeya Sewu Indonesia Tbk (SIPD.JK) Income Statement Analysis – Financial Results
- Era Co., Ltd. (002641.SZ) Income Statement Analysis – Financial Results
Athira Pharma, Inc. (ATHA)
About Athira Pharma, Inc.
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 969.00K | 1.05M | 479.00K | 2.00M | 0.00 | 0.00 |
| Gross Profit | -969.00K | -1.05M | -479.00K | -2.00M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 93.79M | 61.46M | 42.79M | 13.29M | 3.79M | 3.59M |
| General & Administrative | 33.30M | 32.55M | 21.23M | 6.71M | 1.66M | 1.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.30M | 32.55M | 21.23M | 6.71M | 1.66M | 1.42M |
| Other Expenses | -1.63M | -5.16M | -8.84M | -1.32M | -754.00K | -164.00K |
| Operating Expenses | 125.47M | 88.86M | 55.19M | 18.67M | 4.70M | 5.01M |
| Cost & Expenses | 125.47M | 88.86M | 55.19M | 18.67M | 4.70M | 5.01M |
| Interest Income | 7.64M | 3.22M | 337.00K | 124.00K | 51.00K | 85.00K |
| Interest Expense | 0.00 | 24.32M | 3.00K | 367.00K | 346.00K | 9.00K |
| Depreciation & Amortization | 969.00K | 1.05M | 479.00K | 2.00M | 2.00K | 5.01M |
| EBITDA | -116.70M | -94.59M | -54.37M | -19.01M | -4.82M | -79.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -125.47M | -104.02M | -64.02M | -20.00M | -5.45M | -5.01M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.79M | 8.38M | 9.17M | 40.00K | 288.00K | -88.00K |
| Income Before Tax | -117.67M | -95.64M | -54.85M | -19.96M | -5.16M | -5.10M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -8.38M | -479.00K | -1.32M | -459.00K | -76.00K |
| Net Income | -117.67M | -87.26M | -54.37M | -18.63M | -4.70M | -5.10M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.10 | -2.31 | -1.47 | -0.57 | -0.14 | -0.82 |
| EPS Diluted | -3.09 | -2.31 | -1.47 | -0.57 | -0.14 | -0.82 |
| Weighted Avg Shares Out | 38.02M | 37.73M | 36.92M | 32.49M | 32.62M | 6.19M |
| Weighted Avg Shares Out (Dil) | 38.02M | 37.73M | 36.92M | 32.49M | 32.62M | 6.19M |
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
ATH-1105 demonstrated consistent improvements across measures of motor function, nerve function, and neurodegeneration in a TDP-43 mouse model of ALS
Athira Pharma Highlights Therapeutic Potential of Fosgonimeton in Presentation of Additional Biomarker Data in Mild-to-Moderate Alzheimer's Disease Patients from ACT-AD Phase 2 Study at CTAD Conference
Fosgonimeton treatment-related reductions in biomarkers of neurodegeneration (NfL) and neuroinflammation (GFAP) significantly correlated with improvements in clinical outcomes as assessed by the GST, a composite score of cognition (ADAS-Cog11) and function (ADCS-ADL23)
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS HGF/MET small molecule positive modulator provides neuroprotection and improves motor and nerve function in a TDP-43 mouse model of ALS
Athira Pharma to Present Additional Biomarker Data from ACT-AD Phase 2 Study of Fosgonimeton at the 2022 Clinical Trials on Alzheimer's Disease (CTAD) Conference
Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration Fosgonimeton demonstrates improvement on diverse biomarkers of neurodegeneration
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
Independent, unblinded, interim efficacy and futility analysis of Phase 2/3 LIFT-AD study in mild-to-moderate Alzheimer's disease patients supports potential clinically meaningful activity of fosgonimeton without background acetylcholinesterase therapy and mitigates program risk
Athira Pharma to Present at Stifel 2022 Healthcare Conference
BOTHELL, Wash., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that members of Athira's management team will participate in...
Athira Pharma to Present Preclinical Data Highlighting Therapeutic Potential of HGF/MET Platform in Neurodegenerative Disorders at Neuroscience 2022 Conference
Data supports neuroprotective and disease modifying potential in models of Parkinson's disease and diabetic neuropathy Data supports neuroprotective and disease modifying potential in models of Parkinson's disease and diabetic neuropathy
Trading Ideas On The Upcoming CTAD 2022 Conference
The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.
Athira Pharma: Fosgonimeton May Outperform Lecanemab In Alzheimer's
Athira Pharma's stock has sold off some months ago on its Alzheimer's drug candidate Fosgonimeton not meeting a primary endpoint in a randomized Phase 2 trial. The monotherapy arm did show remarkable efficacy, which appears stronger than 27% slowing of...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Athira Pharma, Inc
Wilmington, Delaware--(Newsfile Corp. - August 24, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Athira Pharma, Inc. (NASDAQ: ATHA) on behalf of stockholders.To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-athira-pharma-inc.To...
Source: https://incomestatements.info
Category: Stock Reports